-
公开(公告)号：US11827646B2
公开(公告)日：2023-11-28
申请号：US17099578
申请日：2020-11-16
Applicant: Hoffmann-La Roche Inc. , PTC Therapeutics, Inc.
Inventor： Hasane Ratni , Luke Green , Marla L. Weetall , Nikolai A. Naryshkin
IPC: C07D519/00
CPC classification number: C07D519/00
Abstract: The present invention provides compounds of formula (I)
wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.-
公开(公告)号：US20230374014A1
公开(公告)日：2023-11-23
申请号：US17999194
申请日：2021-05-18
Applicant: Hoffmann-La Roche Inc.
Inventor： Guido GALLEY , Katrin GROEBKE ZBINDEN , Wolfgang GUBA , Daniel HUNZIKER
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: The invention relates to a compound of formula (I), wherein R1-R3 and A1-A3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
-
公开(公告)号：USD1004611S1
公开(公告)日：2023-11-14
申请号：US29758646
申请日：2020-11-17
Applicant: Hoffmann-La Roche Inc.
Designer： Silvia Elena Molero Leon , Hélène Jeanne Sahri , Turap Tasoglu
Abstract: FIG. 1 is a front view of a display screen or portion thereof with graphical user interface showing the claimed design;
FIG. 2 is a front view of a display screen or portion thereof with graphical user interface showing an alternative embodiment of the claimed design;
FIG. 3 is a front view of a display screen or portion thereof with graphical user interface showing an alternative embodiment of the claimed design; and,
FIG. 4 is a front view of a display screen or portion thereof with graphical user interface showing an alternative embodiment of the claimed design.
The broken lines in the figures around the graphical user interface show a display screen or portion thereof, and form no part of the claimed design. The other broken lines in the figures show portions of the graphical user interface that form no part of the claimed design.-
公开(公告)号：US20230357773A1
公开(公告)日：2023-11-09
申请号：US18164151
申请日：2023-02-03
Applicant: HOFFMANN-LA ROCHE INC. , DICERNA PHARMACEUTICALS, INC.
Inventor： Søren OTTOSEN , Henrik MUELLER , Hardean ACHNECK , Douglas M. FAMBROUGH , Bob Dale BROWN
IPC: C12N15/113 , A61P31/20 , A61K45/06 , A61K31/7088
CPC classification number: C12N15/1131 , A61P31/20 , A61K45/06 , A61K31/7088 , C12N2310/11 , C12N2310/322 , C12N2310/321 , C12N2310/315 , C12N2310/3519 , C12N2310/312 , C12N2320/32 , C12N2320/35 , C12N2320/31
Abstract: The present invention provides oligonucleotides for use in the treatment of hepatitis B or hepatitis B virus infection in a human patient.
-
公开(公告)号：US20230357431A1
公开(公告)日：2023-11-09
申请号：US18308290
申请日：2023-04-27
Applicant: Hoffmann-La Roche Inc.
Inventor： Diana DAROWSKI , Martina GEIGER , Christian KLEIN
CPC classification number: C07K16/3015 , C12N15/63 , A61P35/00 , C07K2319/03 , C07K2319/02 , C07K2319/30 , C07K2317/622 , C07K2317/524 , C07K2317/565
Abstract: The present invention generally relates to activatable antigen binding receptors capable of specific binding to a mutated Fc domain. The antigen binding receptors of the invention are activatable through (a) protease(s). After activation, the antigen binding receptors are targeted to tumor cells by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. The invention also relates to transduced immune cells expressing the antigen binding receptors of the invention and/or nucleic acid molecules encoding the antigen binding receptors of the present invention. Further provided are kits comprising such cells and/or nucleic acid molecules in combination with tumor targeting antibodies comprising a mutated Fc domain.
-
Patent Agency Ranking
公开(公告)号：US20230340154A1
公开(公告)日：2023-10-26
申请号：US18318466
申请日：2023-05-16
Applicant: Hoffmann-La Roche Inc.
Inventor： Sara Labiano Alminana , Pedro Romero , Genrich Tolstonog , Christine Trumpfheller , Pablo Umana , Marie Catherine Vozenin
CPC classification number: C07K16/40 , A61N5/10 , A61P35/00 , C07K16/2878 , A61K2039/505 , C07K2317/31 , C07K2317/75
Abstract: The present invention relates to combination therapies employing FAP-targeted CD40 agonists, in particular bispecific antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) and at least one antigen binding domain capable of specific binding to CD40, and radiotherapy.
-
公开(公告)号：US20230331682A1
公开(公告)日：2023-10-19
申请号：US18210934
申请日：2023-06-16
Applicant: Hoffmann-La Roche Inc.
Inventor： Cosimo Dolente , David Stephen Hewings , Daniel Hunziker , Daniela Krummenacher , Piergiorgio Francesco Tommaso Pettazzoni , Fabienne Ricklin , Claus Riemer , Juergen Wichmann
IPC: C07D239/88 , C07D401/12 , C07D401/14
CPC classification number: C07D239/88 , C07D401/12 , C07D401/14
Abstract: The invention relates to a compound of formula (I)
Wherein A, L, R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.-
公开(公告)号：US11780919B2
公开(公告)日：2023-10-10
申请号：US17218948
申请日：2021-03-31
Applicant: Hoffmann-La Roche Inc.
Inventor： Maria Amann , Juergen Peter Bachl , Alexander Bujotzek , Carina Cantrill , Harald Duerr , Janine Faigle , Sabine Imhof-Jung , Christian Klein , Thomas Kraft , Estelle Marrer-Berger , Ekkehard Moessner , Laurene Pousse , Petra Rueger , Johannes Sam , Roland Staack , Dietrich Tuerck , Pablo Umana , Joerg Zielonka
CPC classification number: C07K16/2809 , A61K45/06 , A61P35/00 , C07K16/2878 , C07K16/30 , C07K16/468 , A61K2039/505 , C07K2317/565 , C07K2317/622
Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
-
公开(公告)号：US20230312837A1
公开(公告)日：2023-10-05
申请号：US18208029
申请日：2023-06-09
Applicant: Hoffmann-La Roche Inc.
Inventor： Floriane Bahuon , Jean Coudane , Vincent Darcos , Benjamin Nottelet , Sulabh Pravinchandra Patel , Gregoire Schwach
CPC classification number: C08G81/00 , A61K9/0051 , A61K45/06
Abstract: Disclosed herein are novel copolymers of poly(ε-caprolactone) (PCL) and polydopamine (PDA), optionally further comprising a PEG chain, methods for making them as well as their use in pharmaceutical preparations, especially implants or in situ gelling depots, for the treatment of ocular disorders or eye diseases.
-
公开(公告)号：US20230312473A1
公开(公告)日：2023-10-05
申请号：US18194423
申请日：2023-03-31
Applicant: Genentech, Inc. , Hoffmann-La Roche Inc.
Inventor： Fabienne HOFFMANN-EMERY , Manuel KONRATH , Christian LAUTZ , Katrin Monika NIEDERMANN , Jonathan Ugo ORCEL , Diane Elizabeth CARRERA
IPC: C07D213/61 , C07D207/08 , C07D207/16 , C07D239/38 , C07D491/08
CPC classification number: C07D213/61 , C07D207/08 , C07D207/16 , C07D239/38 , C07D491/08 , C07B2200/13
Abstract: Processes for preparing biheteroaryl compounds are provided, including the biheteroaryl compound 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine. Among other advantages, the processes provide for: the use of solvents that are relatively non-toxic and inexpensive; reduced usage of expensive precious metal catalysts; reaction temperature reduction in certain steps; the use of relatively non-toxic oxidation agents; the use of inexpensive transition metal catalysts; a reduction of molar ratios of certain reactants thereby improving process efficiency while reducing cost and waste; significantly higher reactant concentrations in certain steps; elimination of the need for multiple chromatographic purification steps; elimination of the need for certain extraction steps using organic solvent; and provide for higher yield and improved purity.
-
-
-
-
-
-
-
-
-
Search Results
5327
records
(took 0.034 seconds)
